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C H a r r r n  1 1
7t SUMMARY
The work described in this thesis focuses on the features of negatively charged human
serum albumins (NCAs) with the aim to produce intrinsic active drug carriers for anti-
HIV-1 therapy. The NCAs, earlier developed in our laboratory, are proteins in which extra
negative charges are introduced by modification of the e-NH2 groups of the lysines either
by succinylation or aconitylation. This results in the prototypes Suc-HSA and Aco-HSA,
modified proteins that displayed a high potency against HIV-1 replication with IC5e values
in the low nanomolar range. Preliminary studies already indicated that the mechanism of
antiviral action was explained by disruption of the early virus bindinlusion events in the
replication cycle of HIV-I. To characterize the multiple mechanisms of the NCAs involved
in inhibition of HlV-growth and to investigate the possibilities of using these antivirally
active proteins as a drug-targeting device for the antiviral drug AZT the studies described
in this thesis were performed. The project was financially supported by the Dutch
Organization for Scientific Research (NWO). The studies were predominantly performed
in the laboratories of the section of Pharmacokinetics and Drug Delivery of the Groningen
Institute of Drug Studies (GIDS) as paÍt of the research school Groningen Utrecht Institute
for Drug Exploration (GUIDE), the Netherlands. Through structural collaborations with
the Central Laboratory of the Netherlands Red Cross Blood Tranfusion Service,
Amsterdam (Dr. I.G. Huisman and Dr. H. Schuitemaker and coworkers), the department of
Virology of the Erasmus University, Rotterdam (Drs. M. Schutten and Prof.Dr. A.D.M.E.
Osterhaus) and the Rega Institute for Medical Research, University of Leuven, Belgium
(Dr. R. Pauwels, Dr. M-P de Bethune, Dr. M. Witvrouw and Prof.Dr. E. de Clercq and
coworkers) the antiviral studies, described in this thesis, could be conducted.
Chapter 1 starts with a summaÍy of some of the advantages of using drug targeting
including "dual targeting" in antiviral therapy. Dual targeting implies the use of carriers
that, apart from delivering adequate amounts of the coupled drug to the wanted cell type
in the body, also contributed thernselves to the required therapeutic effect. In addition to
t49
IChapter 11
the presently known aspects of the AIDS syndrome and the description of the replication
cycle of HIV-1, the possibilities and limitations of drug intervention in this disease are
discussed. Special attention is given to antiviral compounds acting at the early phases in
the replication cycle of HIV. The properties and potentials of soluble CD4, monoclonal
antibodies, certain synthetic peptides, polyanionic compounds and the NCAs are
described. Furthermore the potential use of these compounds as dual targeting devices is
discussed.
The mechanism of antiviral action of the NCAs is described in the chapters 2, 3 and, 4.
Components of the viral particle, especially the viral envelope proteins gp120 and gp41., as
well as receptors on the target cells are involved in the penentration of HlV-particles in the
particular target cells. In the chapters 2 and 3 we describe the studies on the interaction of
the NCAs with gp120 employing synthetic peptides composed of 15 up to 36 amino acids
and corresponding to di-fferent parts of the 9p720 envelope protein of HIV-I. Among the
gp120 peptides tested, high affinity binding of the NCAs was observed with the so called "V3
loop" (amino acrds296-330) and the C-terminal part of p720, domains both involved in post-
binding steps of virus and cells. A higher number of negatively charged residues in the
albumins resulted in higher binding affinities. The NCAs mainly bound to the tip of the V3
loop (GPGRAF sequence)/ a sequence that is strongly positively charged. Yet, apart from
the overall charge, the actual amino acid composition appeared to be important for binding
as well, since less positively charged fragments at the C-terminal part of the loop showed a
stronger affinity Íor the NCAs as compared to the N-terminal part of the loop. After the
initial9p120-CD4 binding, but prior to viral entry, the V3loop is suppossed to be cleaved
by a cellular protease. In order to mimic this situation in ztitro, cleaving of the V3 loop at the
GPGRAF domain was performed using thrombin, and this resulted in a complete loss of
affinity for the NCAs as compared with the uncleaved loop. Binding of the NCAs to the V3
and C-terminal oligopeptide was competitively inhibited by heparin and dextran suUate. We
conclude that the mechanism of antiviral activity of the NCAs can (at least partly) be
explained by the interaction with the 9p120 envelope protein and is dependent on the
electrostatic attraction of both components, the presence of hydrophobic amino acids and
the circular conformation of the V3 loop.
In chapter 4 the influence of the NCAs on the entry process of the virus at the cellular level
was investigated. We earlier observed that preincubation of the NCAs with the target cells
seemed to cause an additional inhibitory effect of virus replication. Therefore MT-4 cells,
commonly used in in ztitro screenings assays, and freshly isolated human peripheral blood
mononuclear cells (PBMCs), used as a representative of the target cells for HIV in aiao,
were used to identify a possible membrane component, other than the CD4 receptor, that
could be involved in this aspect of the antiviral activity of the NCAs. We observed that the
NCAs avidly bind to MT-4 cells. Two binding sites were inferred for both NCAs. The
binding of the NCAs to MT-4 cells could be inhibited by polyinosinic acid, heparin and
dextran sulfate, strongly suggesting the involvement of a binding site for polyanionic
substrates. Interestingly the binding of the NCAs to PBMCs was greatly influenced by the
activation status of the PBMCs. Phytoheamagluttin-(PHA) prestimulated PBMCs were
used in this study since the actívated cell type is more characteristic for the situation in
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compared to unstimulated PBMCs. These results suggest that PHA-prestimulation
increases the expression of polyanionic binding sites on PBMCs. We therefore conclude
that binding to lymphocytes-receptors may represent one of the components in the multi-
mechanistic antiviral activity of the NCAs. Furthermore, these binding sites for the NCAs
on the target cells for HIV aÍe attractive target sites for the NCAs as a drug-carrier for the
specific delivery of anti-retroviral compounds to lymphocytes.
In order to investigate whether Suc-HSA is able to preserve its potency in an in orzro situation,
in chapter 5 we analyzed the antiviral effect of Suc-HSA on HIV-1 replication in the presence
of whole human plasma instead of commonly used tissue culture medium. We observed no
changes in the antiviral effect of Suc-HSA when tested in tissue culture medium, 30%
plasma, or whole blood when CPDA-1 (cihate-phosphate-dextrose-adenine 1) was used as
the anticoagulant. However, a dramatic decrease (greater than 99%) in the antiviral activity
was observed when these experiments were performed in plasma prepared from blood
using heparin as anticoagulant. In the present study we demonstrate that heparin largely
reduces Suc-HSA activity on HIV replication in the same concentration in which if affects
binding of Suc-HSA to the envelope protein gp120 and in particular its V3 domain. In the
same concentration range, heparin reduced binding of Suc-HSA to MT-4 cells, an other
HTLV-I transformed cell line. We concluded that heparin can displace Suc-HSA from its
binding sites on the hybrid lymphoid cells as well as on HIV-1 particles.
In chapter 6 additional studies involving the multi-mechanistic antiviral activity of the
NCAs are described. We demonstrated that syncytium formation of HIV infected and
uninfected T-cells is inhibited at concentrations of l-4 p"{ml of the NCAs. The gp120
mediated virus/cell binding process however was inhibited by the NCAs at about a 10 fold
higher concentrations. Addition of Suc-HSA to target cells incubated with HIV-1 could be
delayed until 50 minutes after infection before loss of activity occurred. These experiments
demonstrate that in addition to the direct influence of the NCAs on the virus entry,
inhibitory effects on syncytium formation and gp120-CD4 binding can be expected, that is
if sufficiently high enough concentrations are attained in the whole organisrn.
Furthermore we investigated whether the NCAs give rise to the production of NCA
resistant HIV-1 strains. Interestingly Suc-HSA dispiayed an unchanged activity against a
Suc-HSA pressured strain as compared with the control HIV-1 IIIB strain. In contrast,
chronic exposure oÍ Aco-HSA to HIV-1 resulted in ten fold reduced ability of HlV-growth
inhibition by Aco-HSA, indicating a moderate development of drug resistance to Aco-HSA.
These results imply that Suc-HSA should probably be preferred in long term treatments in
which a minimal development of drug resistance is required.
In order to develop a dual-targeting device using AZT and the NCAs, we fust checked
whether both types of antiviral agents did antagonize each other. We rather observed a
moderate synergistic activity against HIV-1 with the combination of Suc-HSA and AZT and
also with Aco-HSA and AZT. This result favours a combined use of the drugs: lower doses
of both drugs can be anticipated to be effective whereas the severity of side effects and
toxicity of such a combination could be lower. At the same time, using AZT,4.JCA
combinations or conjugates, the emergence of resistant virus strains could be postponed.
When AZT (in its monophosphate form) was covalently coupled to the NCAs, and added




NCA-AZTMP conjugates was dernonstrated as compared to NCAs alone. This afforded a
clear illustration of a dual activity of these preparations.
In order to optimize the coupling efficiency of the monophosphate derivative of AZT to
proteins using watersoluble carbodiimide (EDCD the use of N-hydroxy-sulfosuccinimide
(NHS) in the conjugation reaction was investigated in chapter 7. The couphngs efficiency
was greatly improved by the use of this second activator of the conjugation reaction. The
hydrolysis of the activated AZTMP intermediate, responsible for the low degree of
conjugation in the earlier method, was decreased considerably since the activated phosphate
gïoup was converted into an activated ester by addition of NHS. In order to minimize the
use of con'rpounds needed for the preparation of AZTMP-protein conjugates, we used an
experimental design to determine the reaction conditions in which a conjugate with two
AZTMP-molecules per molecule oÍ neo-glycoprotein would be produced. In addition a low
proportion of cross-linked conjugates was desired. We demonstrated that the the optimal
conditions Íor coupling 1-2 mole of MTMP to 1 mole of protein were the use of 50 mg
protein,4 mg of AZTMP, an incubation time of 30 h, and an NHS amount of 8 to 15 mg in
the reaction mixfure.
Chapter 8 describes the antiviral activity of the NCAs if tested against patient HlV-isolates
versus HlV-laboratory strains. The phenotypically distinct patient HIV-1 isolates, so called
primary isolates, are more representative Íor the virus strains present in HlV-infected
persons compared to the commonly used laboratory HlV-strains. The latter usually
undergo multiple passages in the particular cell lines and have been shown to loose some
important viral-specific characteristics. In the present study both Suc-HSA and Aco-HSA
were shown to potently inhibit replication of primary HIV-1 variants, independent of the SI
capacity oÍ the HIV-1 variant. A distinct activity was found against clinical isolates albeit in
about a 10 to 100 Íold higher concentrations as compÉred to results earlier found against the
laboratory strains. In addition in this chapter the effect on virus/cell fusion by the NCAs was
demonstrated since inhibition of the syncyctium formation and the absence of proviral DNA
products in cells inoculated with HIV-1 in the presence of Suc-HSA or Aco-HSA was
observed.
In chapter 9 we investigated whether the NCAs could also exhibit an antiHIV efhcacy in
uiz,o. We therefore used a recently developed chimeric, human to mouse, HIV infection
model, in which CBA/N mice were intraperitoneally grafted with human lymphocytes,
resulting in an acute graft versus host reaction (GvHD), with highly activated immune
competent cells. In the present study we analyzed the plasma disappearance and organ
distribution of both compounds after i.v. and i.p. injections. This pharmacokinetic
screening enabled us to establish a dosage regimen by which a significant antiviral activity
in mice should be expected. I.v. injections of 10 mg to 300 mykg for both NCAs showed a
first order kinetic profile, in which a linear correlation between the area under the curve
(AUC) and the dose was observed. This in contrast to the saturation kinetics of the NCAs
earlier found in rats. Blood concentrations of the NCAs were significantly influenced by
preinjections of an excess of formaldehyde treated albumin (Form-HSA), a known inhibitor
of scavenger receptor mediated uptake. Organ distribution studies showed an appreciable
accumulation of the NCAs in liver. Treatment with Form-HSA however lowered the tissue
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indicates that in the mouse scavenger-receptor mediated uptake is not the sole mechanisrn
for accumulation in these organs. Suc-HSA was rapidly absorped from the peritoneal space
into the general circulation after intraperitoneal injections of 300 mg/kg Suc-HSA, resulting
in a final bioavailability of about 0.45.
Dosages of 0.3 to 300 mg&g Suc-HSA were evaluated for their in oizo neutralizing capacity
in this human to mouse chimeric model for. HIV-1 IIIB challenge was performed
approximatgly one hour after grafting of the human PBMC and long before the
characteristic activation of the human PBMC graft takes place. Intraperitoneal injection of 3
mg/kg Suc-HSA, given within 30 to 15 minutes before the mice were challenged with the
virus, was sufficient to protect these mice against infection with the HIV-1 lllB-strain.
These results irnply for the fust time that the NCAs are not only effective in anti-HIV-1
screenings tests in uitrobwt also can exhibit potent anti-HlV-l efÍect in uiuo.
Finally in chapter 10 the results of the abovementioned studies are discussed and further
perspectives for drug delivery of antivirals are mentioned. We concluded that the NCAs
are able to serve as intrinsically active drug carriers to taÍget other anti-retroviral
compounds, such as AZT, to the target cells of HIV, while the NCAs can interfere with
early events in the HIV replication cycle themselves. Future studies will be focused on the
exploration of the NCAs for in aiao efficacy studies in animal infection models and HIV-
patients.
In addition, by exploring the necessary Íeatures to obtain a potent anti-HIV compound,
such as the introduction of negatively charged as well as hydrophobic parts, even more
versatile anti-HIV compounds can potentially be developed. Within this scope, the
characterization of the binding sites on HIV target cells for negatively charged components
is of much relevance, since the general knowlegde may provide more optimal drug carriers
with higher affinities for these cells. In addition the cellular processing of the particular
drug targeting preparations and the eÍficay of dual-targeting devices of NCAs and other
antiviral conjugates should be further investigated to optimize targeted therapy for HIV
infections.
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